StemRIM (TSE: 4599)
Health Care · Biotechnology · JP
¥164.00
-6.29% today · -44.2% 1Y
StemRIM (TSE: 4599) operates in the Biotechnology industry within the Health Care sector. The company is valued at $65.11M and employs 45 people.
Over the last twelve months the share price has lost 44.2%, trading between 158.00 and 368.00.
Tweenvest scores StemRIM across four factors: quality 41/100, value 12/100. Its strongest factor is quality.
4599 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $65.11M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -29.63
- Dividend yield
- —
- Beta (5Y)
- 1.12
- 52-week high
- ¥368.00
- 52-week low
- ¥158.00
- Avg volume (3M)
- —
- Shares outstanding
- 62.68M
- Employees
- 45
- Next earnings
- —
About StemRIM
StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently undergoing Phase II clinical trials for a range of conditions such as epidermolysis bullosa, cerebral infarction, osteoarthritis, chronic liver disease, and cardiomyopathy. Beyond PJ1, StemRIM is also advancing PJ2, another regeneration-inducing medicine utilizing novel peptides A and B; PJ3, a biologic protein designed to promote regeneration; PJ4, a device for collecting a patient's own cells for therapeutic purposes; and PJ5, a stem cell-based gene therapy. Established in 2006, StemRIM is headquartered in Ibaraki, Japan.
- ISIN
- JP3399690001
- Founded
- 2006
- Listed since
- Aug 9, 2019
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| BIO-FD&C Co.,Ltd.KOSDAQ: A251120 | $66.79M | ₩10,240.00 | +1.19% |
| Curasight A/SNGM: CURAS | $66.59M | Dkr— | — |
| Bonus BioGroup Ltd.TASE: BONS | $66.29M | ₪0.18 | +2.92% |
| Lytix Biopharma ASAOB: LYTIX | $65.15M | Nkr8.00 | -2.44% |
| CORESTEMCHEMON Inc.KOSDAQ: A166480 | $64.85M | ₩1,949.00 | -16.71% |
| Spero Therapeutics, Inc.NasdaqGS: SPRO | $64.64M | $1.11 | -1.77% |
| XBiotech Inc.NasdaqGS: XBIT | $64.63M | $2.12 | -7.42% |
| iNtRON Biotechnology, Inc.KOSDAQ: A048530 | $64.53M | ₩2,785.00 | -2.11% |
Figures last refreshed Oct 18, 2026.